Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous t

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Be

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% cha

Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or H

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announc

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Du

PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announc

New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recogn

Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berge

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law P

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national sharehol

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action law

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recogn

PHILADELPHIA, Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announc

Bank of America Corp DE increased its position in ADMA Biologics Inc (NASDAQ: ADMA) by 107.5% in the

Asceniv drives ADMA's growth with rising adoption and real-world evidence, while competitive pressur

ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key

ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lower

Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, s

Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowe

U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lower

Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other

ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 mill

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst

The FDA approval represents the final study report for the Pediatric assessment as required in the p

Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.

ADMA Biologics stock rebounds premarket after a 30% drop tied to short seller claims, as the company

ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-e

ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off po

Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See wha

ADMA Biologics shares drop after Culper Research short report alleges financial misreporting; compan

ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-e

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.21 per share which beat the analyst c